Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

The goal of this clinical trial is to learn if Tirzepatide (Zepbound) can decrease bowelfrequency in patients that have an ileal‐pouch anal anastomosis (IPAA or pouch) betterthan standard of care anti‐diarrheal therapy.The main question it aims to answer is:Does Tirzepatide reduce bowel frequency better than standard of care anti‐diarrhealtherapy in patients that have a pouchParticipants will:Visit the clinic 5 times, answer questions about symptoms daily, be assigned to take thestudy product as instructed and provide a stool sample 4 times.